EMMAC Life Sciences Plc | European Medical Cannabis Company

Medical Cannabis

EMMAC is bringing together the latest science and research into the medical benefits of cannabis with pioneering cultivation, extraction and production to establish itself as the European leader in the production and supply of medical cannabis.

Research

EMMAC is at the forefront of the global medical cannabis industry working with research institutions to deliver clinical data regarding the efficacy of medical cannabis for pain and the potential public health benefits for patients.

CBD and Cannabinoids

EMMAC is capitalising on the rapidly growing CBD and cannabinoids market across Europe, leveraging its genetics and its technology and working on the benefits of CBD and other cannabinoids that are extracted from the cannabis plant.

Imperial College London & EMMAC Life Sciences

EMMAC announces pioneering research collaboration with Imperial College London

The partnership between EMMAC and Imperial College London has been forged to deliver a long-term comprehensive research programme designed to shape the future of the medical cannabis therapeutic industry.

View the press release

Find out more

EMMAC’s European Operations

EMMAC has developed unique supply and distribution partnerships across Europe to establish itself not only as a thought leader at the very forefront of research into the medical benefits of cannabis but also a European leader in the production and supply of medical cannabis, hemp and other derivative products.

Leadership Team

EMMAC Across Europe

EXPERIENCE & EXPERTISE

Leveraging decades of medical cannabis experience through a highly skilled board of advisors, management and consultants

Events & Press Releases

Upcoming Events

Cannabis Europa Paris

8th February, 2019

Press Releases

5th February 2019EMMAC Announces Turnkey GMP Facility in Malta to be Group Import and Distribution Hub

EMMAC granted a Letter of Intent under terms of the Production of Cannabis for Medicinal Use Act 2018 EMMAC, the European independent medical cannabis company, is pleased to announce

29th January 2019Announcing the acquisition of leading Swiss wellness CBD company Blossom

EMMAC Life Sciences PLC (“EMMAC” or the “Company”) is pleased to announce the acquisition of Blossom, a market-leading Swiss wellness CBD company. The acquisition provides EMMAC with a revenue-making

22nd January 2019Acquisition of a majority interest in Medalchemy, a GMP certified laboratory, in Alicante Spain

Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to import, research, manufacture and export medical cannabis.

EMMAC Life Sciences PLC
Audley House, 12-12a Margaret Street, London, W1W 8RH
[email protected]

The European Independent Medical Cannabis Company